Abstract

This project will expand upon the applicants' previously developed computer simulation model of advanced HIV disease and OI's to derive one which encompasses the full natural history and spectrum of HIV disease, and incorporate HIV-RNA as a predictor of disease progression. They will incorporate into the model data from randomized trials of combination antiretroviral therapy as well as from recent OI prophylaxis trials. Using this expanded model and up-to-date clinical, cost, and quality of life data, they will estimate the cost and cost-effectiveness of different HIV management strategies for individuals and groups of patients throughout the course of the disease. Building upon the intellectual foundation and working relationships they have previously established, they propose to examine specific hypotheses related to: 1) the comparative efficacy of early, aggressive intervention with antiretroviral therapy; 2) the relative performance of combination antiretroviral therapy compared to OI prophylaxis, and 3) the impact of new developments in OI research in refining the role of prophylaxis. Finally, they will use the results of these analyses to derive implications for clinical practice. The ultimate objective is to provide timely information which will be useful to clinicians and policy makers in developing rational approaches for the management of HIV.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI042006-05
Application #
6373718
Study Section
Special Emphasis Panel (ZAI1-DET-A (J1))
Program Officer
Williams, Carolyn F
Project Start
1998-04-01
Project End
2002-09-27
Budget Start
2001-04-01
Budget End
2002-09-27
Support Year
5
Fiscal Year
2001
Total Cost
$410,784
Indirect Cost

  Institution

Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199

  Publications

Hyle, Emily P; Fields, Naomi F; Fiebelkorn, Amy Parker et al. (2018) The Clinical Impact and Cost-effectiveness of MMR Vaccination to Prevent Measles Importations among US International Travelers. Clin Infect Dis :
Murray, Eleanor J; Robins, James M; Seage 3rd, George R et al. (2018) Using Observational Data to Calibrate Simulation Models. Med Decis Making 38:212-224
Neilan, Anne M; Dunville, Richard; Ocfemia, M Cheryl Bañez et al. (2018) The Optimal Age for Screening Adolescents and Young Adults Without Identified Risk Factors for HIV. J Adolesc Health 62:22-28
Levison, Julie H; Regan, Susan; Khan, Iman et al. (2017) Foreign-born status as a predictor of engagement in HIV care in a large US metropolitan health system. AIDS Care 29:244-251
Linas, Benjamin P; Morgan, Jake R; Pho, Mai T et al. (2017) Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1. Open Forum Infect Dis 4:ofw266
Borre, Ethan D; Hyle, Emily P; Paltiel, A David et al. (2017) The Clinical and Economic Impact of Attaining National HIV/AIDS Strategy Treatment Targets in the United States. J Infect Dis 216:798-807
Murray, Eleanor J; Robins, James M; Seage, George R et al. (2017) A Comparison of Agent-Based Models and the Parametric G-Formula for Causal Inference. Am J Epidemiol 186:131-142
Losina, Elena; Hyle, Emily P; Borre, Ethan D et al. (2017) Projecting 10-year, 20-year, and Lifetime Risks of Cardiovascular Disease in Persons Living With Human Immunodeficiency Virus in the United States. Clin Infect Dis 65:1266-1271
Freedberg, Kenneth A; Sax, Paul E (2017) Improving on effective antiretroviral therapy: how good will a cure have to be? J Med Ethics 43:71-73
Koullias, Yiannis; Sax, Paul E; Fields, Naomi F et al. (2017) Should We Be Testing for Baseline Integrase Resistance in Patients Newly Diagnosed With Human Immunodeficiency Virus? Clin Infect Dis 65:1274-1281

Showing the most recent 10 out of 66 publications